4 billion injections come back! Stone anti-tumor drug approved clinically

Pharmaceutical Network May 22, the stone pharmaceutical group announced that its subsidiary Shipharmaceutical Group, Qi Pharmaceutical Technology (Shijiazhuang) developed the injection of dositasa (albumin-combined type) has been approved by the State Drug Administration can be carried out in the Mainland clinical trialsData show that the product belongs to the chemical drug 2 category, there is no similar products in the worldIn recent years, China's public medical institutions terminal Dossytasasai injection sales (unit: million yuan)meters of the net data show that in recent years in China's urban public, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal Dositama sai injection sales are more than 4 billion yuan, in the sale of products are dosita sai injectionsinjection with dositasa (albumin-binding) variety competition pattern
it is understood that the stone drug group's injection with dositasa (albumin-combined type) belongs to the chemical medicine category 2, there is no similar products listed in the worldData show that the product using innovative technology to wrap dositasaceansain in human haemoglobin, planned to develop the indications for solid tumorsCompared with dositarace injection, there are two major advantages: first, safety, no hormone pretreatment, high concentration of rapid administration, improve safety and patient compliance
; It is expected that the product will show good anti-tumor treatment results in clinical studiesStone Pharmaceutical Group said it will promote the clinical research of the product, and strive for the product to be marketed as soon as possiblesources: announcement of listed companies, internet database